In conclusion, the results of this Delph‐based consensus study suggest relative confidence of experienced clinicians in prescribing SGLT2 inhibitors to those with diabetes and diabetes‐related foot disease, provided that they do not have a current ulcer and that canagliflozin is not prescribed. This evidence concerns the gene SLC5A2 and ulcer disease.